ArticleAntimicrobial agents and chemotherapy2011
Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- AT-752, a double prodrug of a guanosine nucleotide analog, inhibits yellow fever virus in a hamster model.PLoS neglected tropical diseases · 2022Article
- Adenovirus vectored IFN-α protects mice from lethal challenge of Chikungunya virus infection.PLoS neglected tropical diseases · 2020Article
- Influence of interferon-based drugs on immunological indices in specific prevention.Veterinary world · 2020Article
- Article
- Acute Liver Failure Secondary to Yellow Fever: A Challenging Scenario.Clinical liver disease · 2019Review
- Syrian Hamster as an Animal Model for the Study on Infectious Diseases.Frontiers in immunology · 2019Review
- Review
- Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.Frontiers in immunology · 2018Article
- Infergen Stimulated Macrophages Restrict Mycobacterium tuberculosis Growth by Autophagy and Release of Nitric Oxide.Scientific reports · 2016Article
- Single dose of an adenovirus vectored mouse interferon-α protects mice from lethal EV71 challenge.Antiviral research · 2016Article
- Article
- BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model.Antimicrobial agents and chemotherapy · 2014Article
- Protection against Chikungunya virus induced arthralgia following prophylactic treatment with adenovirus vectored interferon (mDEF201).Antiviral research · 2014Article
- Article
- Type 1 interferon gene transfer enhances host defense against pulmonary Streptococcus pneumoniae infection via activating innate leukocytes.Molecular therapy. Methods & clinical development · 2014Article
- Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs.Journal of virology · 2013Article
- Experimental therapies for yellow fever.Antiviral research · 2013Review
- Article
- Regulators of innate immunity as novel targets for panviral therapeutics.Current opinion in virology · 2012Review
- Extended protection against phlebovirus infection conferred by recombinant adenovirus expressing consensus interferon (DEF201).Antimicrobial agents and chemotherapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Interferon (IFN) is an innate immune response protein that is involved in the antiviral response during viral infection. Treatment of acute viral infections with exogenous interferon may be effective but is generally not feasible for clinical use due to many factors, including cost, stability, and availability. To overcome these limitations, an adenovirus type 5-vectored consensus alpha IFN, termed DEF201, was constructed as a potential way to deliver sustained therapeutic levels of systemic IFN. To demonstrate the efficacy of DEF201 against acute flaviviral disease, various concentrations of the construct were administered as a single intranasal dose prior to virus infection, which resulted in a dose-responsive, protective effect in a hamster model of yellow fever virus (YFV) disease. A DEF201 dose of 5×10(7) PFU/animal administered intranasally just prior to YFV challenge protected 100% of the animals, while a 10-fold lower DEF201 dose exhibited lower, although significant, levels of protection. Virus titers in the liver and serum and levels of serum alanine aminotransferase were all significantly reduced as a result of DEF201 administration at all doses tested. No toxicity, as indicated by weight loss or gross morbidity, was observed in non-YFV-infected animals treated with DEF201. Protection of YFV-infected animals was observed when DEF201 was delivered as early as 7 days prior to virus challenge and as late as 2 days after virus challenge, demonstrating effective prophylaxis and therapy in a hamster model of disease. Overall, it appears that DEF201 is effective in the treatment of YFV in a hamster model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.